SCHEMBL20187641

SCHEMBL20187641

CS(=O)(=O)OCCc1ccc(Br)c(Cl)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.34
ALDH1A1 P00352 4/20 0.34
LMNA P02545 3/20 0.34
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
MMP9 P14780 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
TRPA1 O75762 1/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
CA9 Q16790 1/20 0.33
HPGD P15428 1/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
GLA P06280 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1431818 0.85 PNMT (0.47) ALDH1A1ALOX15TSHRMEN1KMT2A
SCHEMBL2523918 0.84 MAOB (0.41) MAOBALDH1A1LMNATSHRCA1
SCHEMBL20187530 0.83 RAB9A (0.39) ALDH1A1LMNAKDM4EUSP2MMP9
SCHEMBL15137111 0.81 CA1 (0.38) ALDH1A1LMNAKDM4EUSP2MMP9
SCHEMBL14248769 0.81 DAO (0.41) ALDH1A1CA1CA2GLASMN1; SMN2
SCHEMBL15136763 0.80 ALDH1A1 (0.44) ALDH1A1KDM4ETSHRCA1CA2
SCHEMBL20187505 0.79 GPR84 (0.40) ALDH1A1LMNAKDM4EUSP2MMP9
SCHEMBL15229213 0.78 KCNH2 (0.42) ALDH1A1LMNAKDM4EUSP2MMP9
SCHEMBL3258334 0.77 CA2 (0.50) ALDH1A1LMNAKDM4EUSP2MMP9
SCHEMBL1284072 0.76 CA1 (0.43) ALDH1A1LMNAKDM4EUSP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110225911-B Oxadiazolone transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-04-05 CN disclosed
EP-3544979-B1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 EP disclosed
US-10913742-B2 Oxadiazolones as transient receptor potential channel inhibitors GENENTECH, INC. (US) 2021-02-09 US disclosed
EP-3544979-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS H. Hoffnabb-La Roche Ag (CH) 2019-10-02 EP disclosed
US-20190284189-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed
WO-2018096159-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10913742-B2 Oxadiazolones as transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 MAOB 1321/4885ALDH1A1 319/4885LMNA 3855/4885
US-20190284189-A1 OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 MAOB 1321/4885ALDH1A1 319/4885LMNA 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.